| Dr Robert H Payne, MD | |
|
4 Carriage Ln, Suite 100, Charleston, SC 29407-6048 | |
| (843) 763-2222 | |
| (843) 766-5705 |
| Full Name | Dr Robert H Payne |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 52 Years |
| Location | 4 Carriage Ln, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013060573 | NPI | - | NPPES |
| 067670 | Medicaid | SC | |
| P00443329 | Other | SC | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 6767 (South Carolina) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 6767 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Charleston Family Center, Llc | 3274521703 | 2 |
News Archive
A brand new and patented technology has recently been launched that protects patients from buying and using counterfeit medicines. Pharmaceutical companies can now effectively and very economically protect their products and supply chain with this technology, thus avoiding damages and incalculable liabilities resulting from falsified products.
Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine.
Scientists have discovered a genetic cause of extreme thinness for the first time, in a study published today in the journal Nature.
Researchers developed a promising metal-based compound that destroys kidney cancer cells, while leaving normal cells unharmed. The findings may provide a new way of treating kidney cancer, opening the potential for more potent and less toxic therapies that would give cancer patients a better quality of life.
› Verified 5 days ago
| Entity Name | Charleston Family Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619939873 PECOS PAC ID: 3274521703 Enrollment ID: O20040504000681 |
News Archive
A brand new and patented technology has recently been launched that protects patients from buying and using counterfeit medicines. Pharmaceutical companies can now effectively and very economically protect their products and supply chain with this technology, thus avoiding damages and incalculable liabilities resulting from falsified products.
Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine.
Scientists have discovered a genetic cause of extreme thinness for the first time, in a study published today in the journal Nature.
Researchers developed a promising metal-based compound that destroys kidney cancer cells, while leaving normal cells unharmed. The findings may provide a new way of treating kidney cancer, opening the potential for more potent and less toxic therapies that would give cancer patients a better quality of life.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert H Payne, MD 4 Carriage Ln, Suite 100, Charleston, SC 29407-6048 Ph: (843) 763-2222 | Dr Robert H Payne, MD 4 Carriage Ln, Suite 100, Charleston, SC 29407-6048 Ph: (843) 763-2222 |
News Archive
A brand new and patented technology has recently been launched that protects patients from buying and using counterfeit medicines. Pharmaceutical companies can now effectively and very economically protect their products and supply chain with this technology, thus avoiding damages and incalculable liabilities resulting from falsified products.
Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine.
Scientists have discovered a genetic cause of extreme thinness for the first time, in a study published today in the journal Nature.
Researchers developed a promising metal-based compound that destroys kidney cancer cells, while leaving normal cells unharmed. The findings may provide a new way of treating kidney cancer, opening the potential for more potent and less toxic therapies that would give cancer patients a better quality of life.
› Verified 5 days ago